Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/13/2026 | $150.00 | Hold → Buy | Deutsche Bank | |
| 1/8/2026 | $135.00 | Peer Perform → Outperform | Wolfe Research | |
| 12/18/2025 | $130.00 | Market Perform → Outperform | BMO Capital Markets | |
| 12/9/2025 | $270.00 | Buy | Citigroup | |
| 11/24/2025 | $125.00 | Equal Weight → Overweight | Wells Fargo | |
| 11/13/2025 | $105.00 | Sector Outperform | Scotiabank | |
| 10/13/2025 | $95.00 | Neutral | Citigroup | |
| 9/17/2025 | $90.00 | Buy → Hold | Berenberg |
144 - Merck & Co., Inc. (0000310158) (Subject)
8-K - Merck & Co., Inc. (0000310158) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00
Wolfe Research upgraded Merck from Peer Perform to Outperform and set a new price target of $135.00
BMO Capital Markets upgraded Merck from Market Perform to Outperform and set a new price target of $130.00
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098 Webcast:Live and replay webcasts of the call are available here. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scienti
The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors Approvals based on Phase 3 KEYNOTE-B96 trial that demonstrated the KEYTRUDA regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared to placebo plus paclitaxel with or without bevacizumab Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or
CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot
Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098 Webcast:Live and replay webcasts of the call are available here. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scienti
Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)